Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9169250 | DAIICHI SANKYO INC | Compounds modulating c-fms and/or c-kit activity and uses therefor |
Nov, 2027
(4 years from now) | |
US8722702 | DAIICHI SANKYO INC | Compounds modulating c-fms and/or c-kit activity and uses therefor |
Nov, 2027
(4 years from now) | |
US8404700 | DAIICHI SANKYO INC | Compounds modulating c-fms and/or c-kit activity and uses therefor |
Nov, 2027
(4 years from now) | |
US7893075 | DAIICHI SANKYO INC | Compounds modulating c-fms and/or c-kit activity and uses therefor |
May, 2033
(10 years from now) | |
US10730876 | DAIICHI SANKYO INC | Synthesis of a compound that modulates kinases |
May, 2036
(13 years from now) | |
US9802932 | DAIICHI SANKYO INC | Solid forms of a compound modulating kinases |
May, 2036
(13 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8461169 | DAIICHI SANKYO INC | Compounds modulating c-fms and/or c-kit activity |
Apr, 2028
(5 years from now) | |
US9358235 | DAIICHI SANKYO INC | Kinase modulation, and indications therefor |
Jun, 2033
(10 years from now) | |
US10189833 | DAIICHI SANKYO INC | Solid forms of a compound modulating kinases |
May, 2036
(13 years from now) | |
US10435404 | DAIICHI SANKYO INC | Formulations of a compound modulating kinases |
Jul, 2038
(15 years from now) | |
US10961240 | DAIICHI SANKYO INC | Formulations of a compound modulating kinases |
Jul, 2038
(15 years from now) | |
US10941142 | DAIICHI SANKYO INC | Formulations of a compound modulating kinases |
Jul, 2038
(15 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Aug 2, 2024 |
ODE* (ODE*) | Aug 2, 2026 |
Orphan Drug Exclusivity (ODE) | Aug 2, 2026 |
NCE-1 date: 2023-08-03
Market Authorisation Date: 02 August, 2019
Treatment: Treatment of adult patients with symptomatic tenosynovial giant cell tumor (tgct) associated with severe morbidity or functional limitations and not amenable to improvement with surgery
Dosage: CAPSULE;ORAL
39
United States
10
Japan
7
China
7
European Union
6
Korea, Republic of
5
Brazil
5
Canada
5
Australia
4
Singapore
4
Spain
4
Taiwan, Province of China
3
Hong Kong
3
South Africa
3
Israel
2
Portugal
2
Malaysia
2
Russia
2
Colombia
2
New Zealand
2
Mexico
2
Slovenia
2
Hungary
2
Denmark
1
El Salvador
1
Uruguay
1
Guatemala
1
Croatia
1
Costa Rica
1
Norway
1
Philippines
1
Argentina
1
Peru
1
EA
1
Nicaragua
1
Lithuania
1
Cyprus
1
Ukraine
1
Poland
1
Chile
1
RS
1
Ecuador
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic